Slow low-dose oral immunotherapy: Threshold and immunological change

• Published in: Allergology International Vol. 69; no. 4; pp. 601 - 609
• Main Authors: Sugiura, Shiro, Kitamura, Katsumasa, Makino, Atsushi, Matsui, Teruaki, Furuta, Tomoko, Takasato, Yoshihiro, Kando, Naoyuki, Ito, Komei
• Format: Journal Article
• Language: English
• Published: England Elsevier B.V 01.10.2020; JAPANESE SOCIETY OF ALLERGOLOGY; Elsevier
• Subjects: Food allergy; Initial dose; Maintenance dose; Oral food challenges; Oral immunotherapy; Food allergy; LD-OIT; sIgE; AC; TS/Pro; AD; IgE; ITT; AN; OFC; Oral immunotherapy; ASCA; TD; AR; PPS; Oral food challenges; LD-OFC; SLOIT; Maintenance dose; Initial dose; FA; OIT; BA; TS
• ISSN: 1323-8930; 1440-1592
• DOI: 10.1016/j.alit.2020.03.008

We examined the feasibility, efficacy and safety of slow low-dose oral immunotherapy (SLOIT) for egg, milk, wheat allergies, with accepted severity-stratified initial and maintenance doses. Children with food allergies defined by low-dose oral food challenges (LD-OFCs) to hen's egg (cumulative protein dose up to 983 mg, n = 133), cow's milk (287 mg, n = 50), and wheat (226 mg, n = 45) were recruited. Participants were divided into two groups [SLOIT and control (complete avoidance]) based on their preferences. Participants who selected SLOIT were instructed to take the safe dose daily, with monthly increases, aiming to increase the dose by 10 times in one year. The primary outcome was the proportion of participants who passed the LD-OFCs following 1 year of therapy. The participants in SLOIT group ingested their antigen 92.9% of the therapy's day on average. The proportion of participants who passed LD-OFCs was 35.9% (61/170) in the SLOIT group and 8.7% (4/46) in the control group (P < .001); no large differences were observed among allergens. Among the subjects who failed LD-OFCs, the median change in the total dose in the LD-OFC was 235% (interquartile range: 100%–512%) in the SLOIT group and 100% (42%–235%) in the control group (P < .001). Provoked allergic symptoms were observed in only 0.58% (280/48,486) per programmed intake and approximately 50% of the SLOIT group did not experience any obvious allergic symptoms throughout therapy. SLOIT showed significant feasibility, efficacy and safety, providing a promising option to manage patients with severe food allergies. [Display omitted]